Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET

Blood

Volumn 117, Issue 20, 2011, Pages 5314-5320

  Straus, David J ^a   Johnson, Jeffrey L ^b   Lacasce, Ann S ^c   Bartlett, Nancy L ^d   Kostakoglu, Lale ^e   Hsi, Eric D ^f   Schöder, Heiko ^a   Hall, Nathan C ^g   Jung, Sin Ho ^g   Canellos, George P ^c   Schwartz, Lawrence H ^h   Takvorian, Ronald W ⁱ   Juweid, Malik E ^j   Cheson, Bruce D ^k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Dana Farber Cancer Institute   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF IOWA HEALTH CARE   (United States)

^k GEORGETOWN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BONE PAIN; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ESOPHAGUS PAIN; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; LEUKEMIA RELAPSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA;

EID: 79956356218     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-314260     Document Type: Article

References (38)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
2. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-3489. (Pubitemid 39564416)
3. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642. (Pubitemid 46237440)
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582. (Pubitemid 44547808)
5. Matasar MJ, McCallen LN, Reidel ER, Ford JS, Oeffinger KC, Straus DJ. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol. 2009;27(suppl): 15s. Abstract 8547.
6. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439. (Pubitemid 46603515)
7. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614-7620. (Pubitemid 46291825)
8. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615-2619. (Pubitemid 30432529)
9. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000;85(9):926-929.
10. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-1079. (Pubitemid 47053777)
11. Frei E 3rd, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE. 5-(3, 3-Dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother Rep. 1972;56(5):667-670.
12. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160-1168. (Pubitemid 41418320)
13. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59. (Pubitemid 43053523)
14. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746- 3752. (Pubitemid 47372616)
15. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11):2678-2687. (Pubitemid 44845624)
16. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-1636. (Pubitemid 19272832)
17. Noordijk EM, Carde P, Dupouy N, et al. Combinedmodality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128-3135. (Pubitemid 46638951)
18. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A (General). 1972;135(2):185-207.
23. Terada Y, Nakamae H, Aimoto R, et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009;28:116.
24. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12(2):153-157.
25. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol. 2010;28(27):4199-4206.
26. Straus D, Juweid M, Kostakoglu L, et al. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood. 2007;110(ASH Annual Meeting Abstracts):Abstract 214.
27. Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol. 2004;15(12):1798-1804. (Pubitemid 40012246)
28. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limitedstage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010;28(9):1611-1615.
29. Olcese F, Clavio M, Rossi E, et al. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. Ann Hematol. 2009;88(9):855-861.
30. Barnes JA, Lacasce AS, Zukotynski K, et al. Endof-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22(4):910-915.
31. Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003;98(5):978-982. (Pubitemid 37022098)
32. Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advancedstage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22(12):2424-2429. (Pubitemid 41115400)
33. Schwenkglenks M, Pettengell R, Szucs TD, Culakova E, Lyman GH. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol. 2010;3:27.
34. Hodgson DC, Gilbert ES, Dores GM, et al. Longterm solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489-1497. (Pubitemid 46759253)
35. Campbell BA, Voss N, Pickles T, et al. Involvednodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.
36. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. In zt J Radiat Oncol Biol Phys. 2009;75(4):1173-1180.
37. Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004;22(8):1532-1533. (Pubitemid 41103643)
38. Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma. Cancer J. 2009;15(2):143-149.